; or and inserting ; and ; and (C) by inserting after subparagraph (E) the following new subparagraph: (F) with respect to any amount expended for a covered outpatient drug which the State is required to exclude from coverage under section 1927(d)(8); or ; and (2) in section 1927(d), by adding at the end the following new paragraph: (8) Restriction on coverage of foreign-made generic drugs (A) In general Beginning January 1, 2025, a State shall exclude coverage of a foreign-made generic covered outpatient drug if there is a generic drug that is manufactured domestically (as described in section 2(b) of the Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act ) that references the same listed drug under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act as the foreign-made generic covered outpatient drug. (B) Definition of foreign-made generic covered outpatient drug For purposes of this paragraph, the term foreign-made generic covered outpatient drug means a covered outpatient drug that— (i) is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act; and (ii) is not a generic drug that is manufactured domestically (as described in section 2(b) of the Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act ). (C) Exceptions Subparagraph (A) shall not apply to a foreign-made generic covered outpatient drug during any period for which the Secretary— (i) has notified the Administrator of the Centers for Medicare & Medicaid Services pursuant to section 2(a) of the Accelerating Movement of Essential Rx Items to Create Access to National Drug Resources for US Government Services Act that the circumstances under paragraph (2), (3), or (4) of such section apply with respect to such drug